B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

Joseph M Tuscano1,2, Jacob Sands1,21Hematology and Oncology, Veterans Affairs, Northern California Health Care System, California, USA; 2Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, California, USAAbstract: The approach to treating autoimmune d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joseph M Tuscano, Jacob Sands
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b914087182554e769cf88838e423aaaa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b914087182554e769cf88838e423aaaa
record_format	dspace
spelling	oai:doaj.org-article:b914087182554e769cf88838e423aaaa2021-12-02T07:18:27ZB cell reductive therapy with rituximab in the treatment of rheumatoid arthritis1177-54751177-5491https://doaj.org/article/b914087182554e769cf88838e423aaaa2009-05-01T00:00:00Zhttp://www.dovepress.com/b-cell-reductive-therapy-with-rituximab-in-the-treatment-of-rheumatoid-a3126https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Joseph M Tuscano1,2, Jacob Sands1,21Hematology and Oncology, Veterans Affairs, Northern California Health Care System, California, USA; 2Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, California, USAAbstract: The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects. At the same time, as more precise therapies are discovered, the etiologies of these diseases become further elucidated. It is now widely accepted that B-lymphocytes play a significant role in the pathogenesis of various autoimmune diseases, the extent of which continues to be the focus of ongoing research. Rheumatoid arthritis is one such disease process that has been the focus of various B-lymphocyte-directed therapeutic trials. In this paper we review the current research available on rituximab as treatment for rheumatoid arthritis. This review details results from four main studies, as well as others, which used rituximab in at least one of the arms in treatment of rheumatoid arthritis. The results are promising and will likely lead to longer term studies as well as a potential focus on B cell subsets.Keywords: rheumatoid arthritis, rituximab, treatment efficacy, autoimmune, B-cells Joseph M TuscanoJacob SandsDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 225-232 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Joseph M Tuscano Jacob Sands B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
description	Joseph M Tuscano1,2, Jacob Sands1,21Hematology and Oncology, Veterans Affairs, Northern California Health Care System, California, USA; 2Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, California, USAAbstract: The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects. At the same time, as more precise therapies are discovered, the etiologies of these diseases become further elucidated. It is now widely accepted that B-lymphocytes play a significant role in the pathogenesis of various autoimmune diseases, the extent of which continues to be the focus of ongoing research. Rheumatoid arthritis is one such disease process that has been the focus of various B-lymphocyte-directed therapeutic trials. In this paper we review the current research available on rituximab as treatment for rheumatoid arthritis. This review details results from four main studies, as well as others, which used rituximab in at least one of the arms in treatment of rheumatoid arthritis. The results are promising and will likely lead to longer term studies as well as a potential focus on B cell subsets.Keywords: rheumatoid arthritis, rituximab, treatment efficacy, autoimmune, B-cells
format	article
author	Joseph M Tuscano Jacob Sands
author_facet	Joseph M Tuscano Jacob Sands
author_sort	Joseph M Tuscano
title	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
title_short	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
title_full	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
title_fullStr	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
title_full_unstemmed	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
title_sort	b cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/b914087182554e769cf88838e423aaaa
work_keys_str_mv	AT josephmtuscano bcellreductivetherapywithrituximabinthetreatmentofrheumatoidarthritis AT jacobsands bcellreductivetherapywithrituximabinthetreatmentofrheumatoidarthritis
_version_	1718399537462116352

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

Ejemplares similares